Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Status:
Not yet recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, single-arm, pilot study. The aim of this study is to
evaluate the efficacy and safety of linperlisib, the PI3K delta inhibitor for patients with
relapsed/refractory large granular T lymphocytic leukemia.